The quantitative representation of the actual group effects separately for cancer type and mortality showed that SERPINB1 was significantly decreased in deceased compared to surviving patients with lung cancer (FC = 0.82; p = 0.03) and healthy controls (FC = 0.83; p = 0.003). This evidence concerns the gene SERPINB1 and lung cancer.